Co-develop anti-L1 monoclonal antibody therapeutic for treating cancer

Published: 2007-12-05 06:56:00

Updated: 2007-12-05 06:56:00

Celltrion Inc. and German biotech company MediGene AG signed a binding memorandum of understanding for the co-development and commercialization of an anti-L1 monoclonal antibody (anti-L1 MAb) for the treatment of cancer in humans covering major cancer indications, Celltrion officials said on November 28.

The L1 protein highly specifically occurs on the cell surfaces of malignant ovarian and ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.